HB-2121
Phase 1Small molecule
HB-2121 is one of 13 small molecule programs targeting Celiac Disease. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Celiac Disease
#DrugCompanyPhaseTrials
1VIOKACE
AbbVieApproved
Advil
KKenvue Brands
Approved
Tylenol
KKenvue Brands
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
TEV-53408
TevaPhase 2
DONQ52
RochePhase 2
Xifaxan
SSalix
Preclinical
Hepatitis B Vaccine
SanofiPreclinical
ZED1227
DDr. Falk Pharma GmbH
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB-2121. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNielsen Fernandez-Becker